Harbor Investment Advisory, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Harbor Investment Advisory, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$144.95 - $152.29 $7,247 - $7,614	-50 Reduced 83.33%	10 $2,000
Q2 2022 Jul 18, 2022	SELL	$83.14 - $145.99 $43,814 - $76,936	-527 Reduced 89.78%	60 $9,000
Q4 2021 Jan 10, 2022	BUY	$99.73 - $148.48 $11,867 - $17,669	119 Added 25.43%	587 $81,000
Q3 2021 Oct 12, 2021	BUY	$98.85 - $138.91 $10,972 - $15,419	111 Added 31.09%	468 $65,000
Q2 2021 Jul 27, 2021	BUY	$65.78 - $105.02 $22,825 - $36,441	347 Added 3470.0%	357 $35,000
Q4 2020 Feb 04, 2021	BUY	$65.07 - $98.24 $650 - $982	10 New	10 $1,000
Q3 2020 Oct 23, 2020	SELL	$59.04 - $77.95 $354 - $467	-6 Closed	0 $0
Q2 2020 Jul 16, 2020	BUY	$29.01 - $74.23 $174 - $445	6 New	6 $0

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Harbor Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Harbor Investment Advisory, LLC with notifications on news.